Zealand Pharma Future Growth
Future criteria checks 3/6
Zealand Pharma is forecast to grow earnings and revenue by 30.1% and 26.7% per annum respectively. EPS is expected to grow by 37.7% per annum. Return on equity is forecast to be 30.7% in 3 years.
Key information
30.1%
Earnings growth rate
37.7%
EPS growth rate
Biotechs earnings growth | 31.1% |
Revenue growth rate | 26.7% |
Future return on equity | 30.7% |
Analyst coverage | Good |
Last updated | 24 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,470 | -322 | 254 | 43 | 6 |
12/31/2025 | 1,140 | -272 | 413 | 86 | 7 |
12/31/2024 | 694 | -383 | -273 | -577 | 7 |
12/31/2023 | 343 | -704 | -449 | -426 | N/A |
9/30/2023 | 343 | -760 | -777 | -757 | N/A |
6/30/2023 | 92 | -986 | -781 | -771 | N/A |
3/31/2023 | 107 | -1,064 | -831 | -822 | N/A |
12/31/2022 | 104 | -966 | -954 | -942 | N/A |
9/30/2022 | 93 | -855 | -999 | -978 | N/A |
6/30/2022 | 104 | -845 | -1,083 | -1,060 | N/A |
3/31/2022 | 114 | -608 | -1,182 | -1,161 | N/A |
12/31/2021 | 109 | -755 | -1,234 | -1,212 | N/A |
9/30/2021 | 158 | -925 | -1,183 | -1,181 | N/A |
6/30/2021 | 161 | -1,012 | -1,085 | -1,071 | N/A |
3/31/2021 | 347 | -909 | -870 | -844 | N/A |
12/31/2020 | 192 | -669 | -714 | -689 | N/A |
9/30/2020 | 301 | -660 | -618 | -580 | N/A |
6/30/2020 | 255 | -545 | -670 | -632 | N/A |
3/31/2020 | 54 | -624 | -698 | -671 | N/A |
12/31/2019 | 41 | -572 | -433 | -409 | N/A |
9/30/2019 | 43 | -508 | -408 | -391 | N/A |
6/30/2019 | 33 | 524 | 927 | -346 | N/A |
3/31/2019 | 28 | 551 | 952 | -320 | N/A |
12/31/2018 | 38 | 581 | 810 | -461 | N/A |
9/30/2018 | 35 | 601 | 853 | -417 | N/A |
6/30/2018 | 74 | -361 | -317 | -310 | N/A |
3/31/2018 | 68 | -346 | -326 | -320 | N/A |
12/31/2017 | 136 | -274 | -286 | -279 | N/A |
9/30/2017 | 306 | -112 | N/A | -64 | N/A |
6/30/2017 | 307 | -100 | N/A | -113 | N/A |
3/31/2017 | 306 | -102 | N/A | -52 | N/A |
12/31/2016 | 231 | -157 | N/A | 41 | N/A |
9/30/2016 | 221 | -138 | N/A | -114 | N/A |
6/30/2016 | 189 | -158 | N/A | -128 | N/A |
3/31/2016 | 188 | -139 | N/A | -120 | N/A |
12/31/2015 | 188 | -114 | N/A | -225 | N/A |
9/30/2015 | 27 | -246 | N/A | -216 | N/A |
6/30/2015 | 78 | -178 | N/A | -149 | N/A |
3/31/2015 | 75 | -147 | N/A | -146 | N/A |
12/31/2014 | 154 | -65 | N/A | -42 | N/A |
9/30/2014 | 151 | -47 | N/A | -50 | N/A |
6/30/2014 | 95 | -98 | N/A | -100 | N/A |
3/31/2014 | 92 | -97 | N/A | -85 | N/A |
12/31/2013 | 7 | -184 | N/A | -170 | N/A |
9/30/2013 | 3 | -191 | N/A | -134 | N/A |
6/30/2013 | 38 | -157 | N/A | -114 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 22Z is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 22Z is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 22Z is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 22Z's revenue (26.7% per year) is forecast to grow faster than the German market (5.4% per year).
High Growth Revenue: 22Z's revenue (26.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 22Z's Return on Equity is forecast to be high in 3 years time (30.7%)